Track Abivax S.A. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Abivax S.A. ABVX Open Abivax S.A. in new tab

113.06 USD
EPS
-5.67
P/B
16.55
ROE
-135.58
Beta
-0.10
Target Price
155.20 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateMay 25, 2026
EPS-5.67
Book Value6.80
Price to Book16.55
Debt/Equity7.05
Growth
Revenue Growth-0.55%
Estimates
Forward P/E-39.62
Forward EPS-2.84
Target Mean Price155.20

DCF Valuation

Tweak assumptions to recompute fair value for Abivax S.A. (ABVX)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Abivax S.A. Logo Abivax S.A. Analysis (ABVX)

France Healthcare Official Website Stock

Is Abivax S.A. a good investment? Abivax S.A. (ABVX) is currently trading at 113.06 USD. Market analysts have a consensus price target of 155.20 USD. This suggests a potential upside from current levels.

Earnings Schedule: Abivax S.A. is expected to release its next earnings report on May 25, 2026. The market consensus estimate for Forward EPS is -2.84.

Investor FAQ

Does Abivax S.A. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Abivax S.A.?

Abivax S.A. is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be May 25, 2026. The company currently has a trailing EPS of -5.67.

Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, develops therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod, which is in Phase 3 clinical development for the treatment of moderately to severely active UC, as well as Phase 2b clinical trials for Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

Exchange Ticker
NASDAQ ABVX

Dividends

Historical Split Corporate Actions

Trades
Trade History
No trades yet
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion